Ginkgo Bioworks Holdings Inc (DNA)

$8.14

+0.96

(+13.37%)▲

Market is closed - opens 8 PM, 26 Nov 2024

Ginkgo Bioworks Holdings Inc Key Statistics

Market Capitalization
$412.7M
Revenue TTM
$218.0M
EBITDA
$-525.8M
Earnings Per Share (EPS)
$-12.89
Profit Margin
-298.78%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-63.51%

Ginkgo Bioworks Holdings Inc share price movements

  • $7.36
    $8.14
    $8.14
    downward going graph

    9.64%

    Downside

    Day's Volatility :9.66%

    Upside

    0.02%

    downward going graph
  • $5.26
    $75.20
    $8.14
    downward going graph

    35.38%

    Downside

    52 Weeks Volatility :93.01%

    Upside

    89.18%

    downward going graph

Ginkgo Bioworks Holdings Inc Returns

PeriodGinkgo Bioworks Holdings IncSector (Materials)Index (Russel 2000)
3 Months
3.3%
2.1%
0.0%
6 Months
-67.43%
4.0%
0.0%
1 Year
-85.36%
17.2%
0.0%
3 Years
-98.31%
10.0%
-21.2%

Analyst Recommendation on Ginkgo Bioworks Holdings Inc

Sell
    7%Buy
    42%Hold
    50%Sell
Based on 14 Wall street analysts offering stock ratings for Ginkgo Bioworks Holdings Inc(by analysts ranked 0 to 5 stars)
Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
1
1
2
Hold
6
6
6
Sell
7
7
7

Analyst Forecast on Ginkgo Bioworks Holdings Inc

What analysts predicted

Upside of 0.74%

Current $8.14
Target $8.20

Insights on Ginkgo Bioworks Holdings Inc

  • Increasing Revenue

    Revenue is up for the last 4 quarters, 34.75M → 89.04M (in $), with an average increase of 25.9% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -217.18M → -56.40M (in $), with an average increase of 285.1% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 54.1% return, outperforming this stock by 140.2%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 33.1% return, outperforming this stock by 131.4%

Ginkgo Bioworks Holdings Inc Financials in INR & Dollars

FY19Y/Y Change
Revenue
54.2M
-
Net Income
-119.3M
-
Net Profit Margin
-220.23%
-
FY20Y/Y Change
Revenue
76.7M
↑ 41.48%
Net Income
-126.6M
↑ 6.1%
Net Profit Margin
-165.16%
↑ 55.07%
FY21Y/Y Change
Revenue
313.8M
↑ 309.4%
Net Income
-1.8B
↑ 1350.64%
Net Profit Margin
-585.22%
↓ 420.06%
FY22Y/Y Change
Revenue
477.7M
↑ 52.21%
Net Income
-2.1B
↑ 14.61%
Net Profit Margin
-440.63%
↑ 144.59%
FY23Y/Y Change
Revenue
251.5M
↓ 47.36%
Net Income
-892.9M
↓ 57.58%
Net Profit Margin
-355.08%
↑ 85.55%
Q2 FY23Q/Q Change
Revenue
80.6M
↓ 0.17%
Net Income
-173.3M
↓ 15.44%
Net Profit Margin
-215.12%
↑ 38.86%
Q3 FY23Q/Q Change
Revenue
55.4M
↓ 31.2%
Net Income
-302.9M
↑ 74.76%
Net Profit Margin
-546.44%
↓ 331.32%
Q4 FY23Q/Q Change
Revenue
34.8M
↓ 37.3%
Net Income
-211.7M
↓ 30.11%
Net Profit Margin
-609.1%
↓ 62.66%
Q1 FY24Q/Q Change
Revenue
37.9M
↑ 9.18%
Net Income
-165.9M
↓ 21.63%
Net Profit Margin
-437.25%
↑ 171.85%
Q2 FY24Q/Q Change
Revenue
56.2M
↑ 48.13%
Net Income
-217.2M
↑ 30.9%
Net Profit Margin
-386.4%
↑ 50.85%
Q3 FY24Q/Q Change
Revenue
89.0M
↑ 58.43%
Net Income
-56.4M
↓ 74.03%
Net Profit Margin
-63.34%
↑ 323.06%
FY19Y/Y Change
Total Assets
697.3M
-
Total Liabilities
195.5M
-
FY20Y/Y Change
Total Assets
675.2M
↓ 3.18%
Total Liabilities
205.1M
↑ 4.93%
FY21Y/Y Change
Total Assets
2.1B
↑ 206.74%
Total Liabilities
503.6M
↑ 145.54%
FY22Y/Y Change
Total Assets
2.5B
↑ 22.61%
Total Liabilities
803.0M
↑ 59.46%
FY23Y/Y Change
Total Assets
1.7B
↓ 34.42%
Total Liabilities
568.2M
↓ 29.25%
Q2 FY23Q/Q Change
Total Assets
2.3B
↓ 5.18%
Total Liabilities
788.4M
↓ 2.62%
Q3 FY23Q/Q Change
Total Assets
2.0B
↓ 11.59%
Total Liabilities
773.7M
↓ 1.87%
Q4 FY23Q/Q Change
Total Assets
1.7B
↓ 17.82%
Total Liabilities
568.2M
↓ 26.56%
Q1 FY24Q/Q Change
Total Assets
1.6B
↓ 5.02%
Total Liabilities
594.5M
↑ 4.63%
Q2 FY24Q/Q Change
Total Assets
1.6B
↑ 2.75%
Total Liabilities
792.2M
↑ 33.25%
Q3 FY24Q/Q Change
Total Assets
1.5B
↓ 8.88%
Total Liabilities
682.9M
↓ 13.79%
FY19Y/Y Change
Operating Cash Flow
-44.7M
-
Investing Cash Flow
-74.6M
-
Financing Cash Flow
410.4M
-
FY20Y/Y Change
Operating Cash Flow
-135.8M
↑ 204.12%
Investing Cash Flow
-67.1M
↓ 10.03%
Financing Cash Flow
90.3M
↓ 77.99%
FY21Y/Y Change
Operating Cash Flow
-253.8M
↑ 86.86%
Investing Cash Flow
-73.3M
↑ 9.14%
Financing Cash Flow
1.5B
↑ 1598.6%
FY22Y/Y Change
Operating Cash Flow
-252.2M
↓ 0.64%
Investing Cash Flow
-67.4M
↓ 8.0%
Financing Cash Flow
95.3M
↓ 93.79%
Q2 FY23Q/Q Change
Operating Cash Flow
-73.5M
↓ 18.82%
Investing Cash Flow
-30.6M
↑ 57.81%
Financing Cash Flow
-1.4M
↑ 55.52%
Q3 FY23Q/Q Change
Operating Cash Flow
-73.6M
↑ 0.02%
Investing Cash Flow
-34.0M
↑ 11.04%
Financing Cash Flow
-315.0K
↓ 77.19%

Ginkgo Bioworks Holdings Inc Technicals Summary

Sell

Neutral

Buy

Ginkgo Bioworks Holdings Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Ginkgo Bioworks Holdings Inc Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks Holdings Inc
-1.57%
-67.43%
-85.36%
-98.31%
-19.57%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-19.29%
-22.98%
-6.09%
16.5%
106.01%
Biontech Se
Biontech Se
6.62%
28.33%
24.67%
-65.3%
465.36%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
-12.52%
67.25%
57.65%
33.12%
110.8%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-3.08%
3.32%
31.85%
151.49%
110.78%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks Holdings Inc
NA
NA
NA
0.0
-0.64
-0.21
NA
14.65
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
18.25
18.25
1.1
44.91
0.17
0.07
NA
272.04
Biontech Se
Biontech Se
160.8
NA
0.04
-3.04
-0.02
-0.01
NA
79.73
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-0.17
-15.01
-0.03
NA
0.25
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
1.18
0.54
-0.03
0.12
NA
60.65
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks Holdings Inc
Sell
$412.7M
-19.57%
NA
-298.78%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$81.1B
106.01%
18.25
33.61%
Biontech Se
Biontech Se
Buy
$27.1B
465.36%
160.8
-15.36%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$31.6B
110.8%
NA
-15.86%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$116.1B
110.78%
32.84
-4.51%

Ginkgo Bioworks Holdings Inc Institutional Holdings

  • BlackRock Inc

    79.14%

  • Two Sigma Advisers, LLC

    59.24%

  • Legal & General Group PLC

    50.91%

  • NORGES BANK

    29.44%

  • Qube Research & Technologies

    29.22%

  • AQR Capital Management LLC

    19.52%

Corporate Announcements

  • Ginkgo Bioworks Holdings Inc Earnings

    Ginkgo Bioworks Holdings Inc’s price-to-earnings ratio stands at None

    Read More

Company Information about Ginkgo Bioworks Holdings Inc

the organism company ginkgo bioworks engineers new organisms to solve challenges across a range of industries from fuels to pharmaceutical production. our biological engineers make use of an in-house pipeline of synthetic biology technologies to design, build, and test new organisms.

Organization
Ginkgo Bioworks Holdings Inc
Employees
1218
CEO
Dr. Jason Kelly Ph.D.
Industry
Healthcare

FAQs